James Helliwell | BiotechTV

top of page

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC

CEO James Helliwell describes Euprexia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses. Coverage brought to you by

Company News

10 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC

Follow BiotechTV

Sponsors

Sponsor Spotlight